SYBX - Synlogic Inc

SYBX - Synlogic Inc

https://www.synlogictx.com

Recent News

Powered by Alpha Vantage

Synlogic Reports Second Quarter 2024 Financial Results

GlobeNewswire • 1 year, 1 month ago • score: 0.22

WINCHESTER, Mass., Aug. 08, 2024 ( GLOBE NEWSWIRE ) -- Synlogic, Inc. ( Nasdaq: SYBX ) , a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update.

Synlogic Reports First Quarter 2024 Financial Results

GlobeNewswire • 1 year, 4 months ago • score: 0.18

CAMBRIDGE, Mass., May 14, 2024 ( GLOBE NEWSWIRE ) -- Synlogic, Inc. ( Nasdaq: SYBX ) , a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update.

Synlogic, Inc. ( SYBX ) Reports Q4 Loss, Tops Revenue Estimates - Barinthus Biotherapeutics ( NASDAQ:BRNS ) , Synlogic ( NASDAQ:SYBX )

Benzinga • 1 year, 5 months ago • score: 0.12

Synlogic, Inc. SYBX came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -54.05%.

Synlogic, Inc. ( SYBX ) Reports Q4 Loss, Tops Revenue Estimates

Zacks Commentary • 1 year, 5 months ago • score: 0.14

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -54.05% and 2.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Synlogic Adopts Limited Duration Stockholders Rights Plan

GlobeNewswire • 1 year, 6 months ago • score: 0.31

Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic drugs to treat cancer, inflammatory, and metabolic diseases in the United States. The company is headquartered in Cambridge, Massachusetts.

52W High

$1.96

52W Low

$0.90

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.54

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.18

EV/Revenue (<3 favorable)

0.35

P/S (TTM) (<3 favorable)

1652.07

P/B (<3 favorable)

1.36

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

11.26%

Institutions (25–75% balanced)

64.65%

Shares Outstanding

11,698,900

Float

3,605,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-0.09

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.07%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—